Medifast (NYSE: MED) released findings from a recent independent survey of 2,000 U.S. adults trying to lose weight, revealing key insights about weight loss medications and lifestyle changes. The survey, conducted by Talker Research, shows that 65% of respondents believe weight loss medications are more effective when combined with lifestyle changes, while 45% agree that medications alone won’t achieve long-term goals.
Notable findings include: 73% would commit to healthy eating and 72% to regular exercise, even if weight loss medications were available. 58% wished for more support in their weight loss journey and would consider a medically supported program with personalized meal plans and support groups.
Studies indicate that FDA-approved GLP-1 medications combined with lifestyle modification programs like OPTAVIA may help achieve an average 15% body weight reduction. Medifast’s approach incorporates both medication support and coaching for comprehensive weight management.
Medifast (NYSE: MED) ha pubblicato i risultati di un recente sondaggio indipendente che ha coinvolto 2.000 adulti americani che cercano di perdere peso, rivelando importanti intuizioni sui farmaci per la perdita di peso e sui cambiamenti nello stile di vita. Il sondaggio, condotto da Talker Research, mostra che il 65% dei rispondenti ritiene che i farmaci per la perdita di peso siano più efficaci se combinati con cambiamenti nello stile di vita, mentre il 45% concorda sul fatto che i farmaci da soli non porteranno a risultati a lungo termine.
I risultati notevoli includono: il 73% si impegerebbe a seguire un’alimentazione sana e il 72% a esercitarsi regolarmente, anche se fossero disponibili farmaci per la perdita di peso. Il 58% desidera maggior supporto nel loro percorso di perdita di peso e prenderebbe in considerazione un programma supportato medicalmente con piani alimentari personalizzati e gruppi di supporto.
Studi indicano che i farmaci GLP-1 approvati dalla FDA, combinati con programmi di modifica dello stile di vita come OPTAVIA, possono aiutare a raggiungere una riduzione media del 15% del peso corporeo. L’approccio di Medifast integra sia il supporto medico che il coaching per una gestione completa del peso.
Medifast (NYSE: MED) publicó los hallazgos de una reciente encuesta independiente de 2,000 adultos en EE. UU. que intentan perder peso, revelando información clave sobre medicamentos para la pérdida de peso y cambios en el estilo de vida. La encuesta, realizada por Talker Research, muestra que el 65% de los encuestados cree que los medicamentos para la pérdida de peso son más efectivos cuando se combinan con cambios en el estilo de vida, mientras que el 45% está de acuerdo en que los medicamentos por sí solos no lograrán objetivos a largo plazo.
Entre los hallazgos destacados, el 73% se comprometería a comer saludablemente y el 72% a hacer ejercicio regularmente, incluso si estuvieran disponibles medicamentos para la pérdida de peso. El 58% deseaba más apoyo en su viaje de pérdida de peso y consideraría un programa apoyado médicamente con planes de comidas personalizados y grupos de apoyo.
Los estudios indican que los medicamentos GLP-1 aprobados por la FDA, combinados con programas de modificación del estilo de vida como OPTAVIA, pueden ayudar a lograr una reducción promedio del 15% del peso corporal. El enfoque de Medifast incorpora tanto apoyo médico como entrenamiento para una gestión integral del peso.
Medifast (NYSE: MED)는 최근 체중 감량을 시도하는 미국 성인 2,000명을 대상으로 진행된 독립 설문조사 결과를 발표하며 체중 감량 약물과 라이프스타일 변화에 대한 주요 통찰을 드러냈습니다. Talker Research가 실시한 이번 설문조사에 따르면, 응답자의 65%가 라이프스타일 변화와 함께할 때 체중 감량 약물이 더 효과적이라고 믿고 있으며, 45%는 약물만으로는 장기 목표를 달성할 수 없다고 동의하고 있습니다.
주목할 만한 결과로는, 73%가 건강한 식단을 유지하겠다고 다짐하고, 72%는 정기적인 운동을 하겠다고 응답했습니다. 비록 체중 감량 약물이 사용 가능하더라도입니다. 58%는 체중 감량 여정에서 더 많은 지원을 원하고, 개인 맞춤형 식단 계획과 지원 그룹을 포함한 의학적으로 지원되는 프로그램을 고려하고 싶어합니다.
연구에 따르면, FDA 승인 GLP-1 약물이 OPTAVIA와 같은 라이프스타일 수정 프로그램과 결합되면 평균 15%의 체중 감소를 달성하는 데 도움이 될 수 있습니다. Medifast의 접근 방식은 포괄적인 체중 관리를 위해 약물 지원과 코칭을 통합하고 있습니다.
Medifast (NYSE: MED) a publié les résultats d’une récente enquête indépendante auprès de 2 000 adultes américains essayant de perdre du poids, révélant des informations clés sur les médicaments pour la perte de poids et les changements de mode de vie. L’enquête, menée par Talker Research, montre que 65 % des répondants estiment que les médicaments pour la perte de poids sont plus efficaces lorsqu’ils sont associés à des changements de mode de vie, tandis que 45 % conviennent que les médicaments seuls ne permettront pas d’atteindre des objectifs à long terme.
Parmi les résultats notables, 73 % se seraient engagés à manger sainement et 72 % à pratiquer régulièrement de l’exercice, même si des médicaments pour la perte de poids étaient disponibles. 58 % souhaitaient un meilleur soutien dans leur démarche de perte de poids et envisageraient un programme médicalement soutenu avec des plans de repas personnalisés et des groupes de soutien.
Des études indiquent que les médicaments GLP-1 approuvés par la FDA, combinés à des programmes de modification du mode de vie comme OPTAVIA, peuvent aider à atteindre une réduction moyenne de 15 % du poids corporel. L’approche de Medifast intègre à la fois un soutien médicamenteux et un coaching pour une gestion complète du poids.
Medifast (NYSE: MED) hat die Ergebnisse einer kürzlich durchgeführten unabhängigen Umfrage unter 2.000 US-Erwachsenen, die versuchen abzunehmen, veröffentlicht und dabei wichtige Erkenntnisse zu Gewichtsverlustmedikamenten und Lebensstiländerungenoffenbart. Die von Talker Research durchgeführte Umfrage zeigt, dass 65% der Befragten glauben, dass Gewichtsverlustmedikamente in Kombination mit Lebensstiländerungen effektiver sind, während 45% zustimmen, dass Medikamente allein keine langfristigen Ziele erreichen werden.
Bemerkenswerte Ergebnisse sind: 73% würden sich verpflichten, gesund zu essen, und 72% zur regelmäßigen Bewegung, selbst wenn Gewichtsverlustmedikamente verfügbar wären. 58% wünschten sich mehr Unterstützung auf ihrem Gewichtsverlustweg und würden ein medizinisch unterstütztes Programm mit personalisierten Ernährungsplänen und Selbsthilfegruppen in Betracht ziehen.
Studien zeigen, dass von der FDA zugelassene GLP-1-Medikamente in Kombination mit Lebensstiländerungsprogrammen wie OPTAVIA helfen können, eine durchschnittliche Gewichtsreduktion von 15% zu erreichen. Der Ansatz von Medifast vereint sowohl medikamentöse Unterstützung als auch Coaching für ein umfassendes Gewichtsmanagement.
While 8 out of 10 U.S. adults trying to lose weight are eager to reach their goal as soon as possible, they agree that weight loss is an ongoing process requiring consistent attention and effort*
Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessary.
The survey of 2,000 nationally representative
Moreover, the survey found that even if weight loss medications were readily available, a majority of respondents would still commit to lifestyle changes to reach their goals. Specifically,
Other notable findings include:
-
More than half (
58% ) of respondents said they wished they had more support on their weight loss journeys. -
58% of respondents said they would be inclined to try a medically supported weight loss program if it offered personalized meal plans and a support group.
“Weight loss is a journey that requires a holistic approach, including proper nutrition, adequate exercise, sufficient sleep, and a healthy mindset,” said Dan Chard, chairman and chief executive officer of Medifast. “The survey results clearly point to a growing need and desire among
Chard added, “With our habit-based and coach-guided lifestyle solution, OPTAVIA, Medifast is uniquely positioned to meet this clear consumer demand. We offer customized programs and the support of coaches who draw upon their own personal weight loss experience – two of the top tools respondents identified as crucial. Our coaches not only help people lose the weight, but also teach them how to keep it off. For more than 40 years, Medifast has committed to championing nutrition and lifestyle changes, aligning perfectly with the needs and wants of those striving to create a healthy lifestyle. As the market continues to grow, we remain dedicated to supporting individuals in achieving their health and wellness goals through a holistic approach that incorporates both lifestyle changes and, where clinically appropriate, weight loss medications.”
Studies have shown that use of FDA-approved GLP-1 medications together with a lifestyle modification program like OPTAVIA may help you achieve an average reduction in body weight of
*This random double-opt-in survey of 2,000 people who are trying to lose weight was commissioned by Medifast between May 2, 2024, and May 8, 2024. It was conducted by market research company Talker Research, whose team members are members of the Market Research Society (MRS) and the European Society for Opinion and Marketing Research (ESOMAR).
About Medifast®:
Medifast (NYSE: MED) is the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, which provides people with a simple yet comprehensive approach to address obesity and support a healthy lifestyle. OPTAVIA’s holistic solution includes lifestyle plans with clinically proven health benefits, scientifically developed products, and a framework for habit creation – all reinforced by independent coach support for customers on their weight loss journeys. Through its collaboration with national virtual primary care provider LifeMD® (Nasdaq: LFMD) and its affiliated medical group, the holistic solution now includes access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature™. Visit the OPTAVIA and Medifast websites for more information and follow @Medifast on X and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204987167/en/
Public Relations: Jessica Oring, Jessica.Oring@medifastinc.com
Source: Medifast
FAQ
What percentage of survey respondents believe weight loss medications work better with lifestyle changes according to Medifast’s 2024 survey?
65% of respondents believe that weight loss medications are more effective when used together with lifestyle changes.
How many people participated in Medifast’s (MED) weight loss survey in May 2024?
2,000 nationally representative U.S. adults who are trying to lose weight participated in the survey.
What percentage of weight reduction can be achieved by combining GLP-1 medications with OPTAVIA according to Medifast’s studies?
Studies show an average reduction in body weight of 15% when combining FDA-approved GLP-1 medications with lifestyle modification programs like OPTAVIA.
What percentage of respondents would commit to healthy eating despite having access to weight loss medications in Medifast’s survey?
73% of respondents said they would still commit to healthy eating even if weight loss medications were readily available.